Vertex’s Price Tag For Taking More Control Of CRISPR-Partnered Candidate: At Least $900m

Change To Partnership Comes After First Positive Pivotal Data For Blood Disorders

 
• By Joseph Haas
  
Sickle cell anemia, 3D illustration showing blood vessel with normal and deformated crescent-like red blood cells
Vertex thinks CTX001 may offer a cure for sickle cell disease, beta thalassemia
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Gene Therapies

More from Advanced Therapies